Categories
Change Password!
Reset Password!
Oxymetazoline hydrochloride has been noted for its potential in treating acquired blepharoptosis (abnormal drooping of one or both upper eyelids) and for cosmetic upper eyelid lifting. This study aimed to consolidate evidence on its effectiveness.
Patients with acquired blepharoptosis experience a remarkable increase in marginal reflex distance following treatment with 0.1% ophthalmic solution of Oxymetazoline.
Oxymetazoline hydrochloride has been noted for its potential in treating acquired blepharoptosis (abnormal drooping of one or both upper eyelids) and for cosmetic upper eyelid lifting. This study aimed to consolidate evidence on its effectiveness.
Investigators conducted a systematic review of studies adhering to PRISMA guidelines. Databases searched included PubMed, Scopus, and Cochrane. They focused on changes in marginal reflex distance (MRD1) with topical Oxymetazoline compared to controls pre and post-treatment.
Analysis of five studies involving 458 patients showed a significant average MRD1 improvement of 1.40 mm with Oxymetazoline (95% Confidence Interval [0.41 mm, 2.40 mm]). Compared to controls, Oxymetazoline led to a greater increase in MRD1 by 0.83 mm (95% Confidence Interval [0.10 mm, 1.55 mm]).
The application of 0.1% Oxymetazoline ophthalmic solution markedly improved MRD1 in patients with acquired blepharoptosis. However, future research is needed to explore its efficacy across different causes of blepharoptosis.
The Laryngoscope
The Use of Oxymetazoline 0.1% Ophthalmic Solution for Acquired Blepharoptosis: A Systematic Review
Mary Newland et al.
Comments (0)